A non-myeloablative conditioning regimen for allogeneic transplantation with clofarabine, cytarabine, and thymoglobulin [antithymocyte globulin] for myelodysplastic syndrome and acute myeloid leukaemia.

Trial Profile

A non-myeloablative conditioning regimen for allogeneic transplantation with clofarabine, cytarabine, and thymoglobulin [antithymocyte globulin] for myelodysplastic syndrome and acute myeloid leukaemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2013

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Clofarabine (Primary) ; Cytarabine (Primary)
  • Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 05 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top